Dr Reddy's Laboratories on Friday said the US health regulator has issued Form 483 with four observations after inspecting its Andhra Pradesh-based API manufacturing facility. The US Food & Drug Administration (USFDA) today completed a GMP inspection at the company's API manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh, the Hyderabad-based drug major said in a regulatory filing.
The inspection was conducted from May 30, 2024 to June 7, 2024, it added.
'We have been issued a Form 483 with four observations, which we will address within the stipulated timeline,' the drug firm said.
As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
RECOMMENDED FOR YOU
Sun Pharma's Dadra Unit Receives USFDA Warning Letter
Jun 19, 2024
Torrent Pharma Receives Form 483 With Five Observations From USFDA
Jun 12, 2024
Sun Pharma, Dr Reddy's Initiate Drug Recalls In US Market Over Manufacturing Issues: USFDA
May 30, 2024
Strides Pharma Reports Profit In Q4; USFDA Approves Generic Gastrointestinal Drug
May 22, 2024
POPULAR